Tat Derivative Polypeptides Modulating Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammation and autoimmune disorders have limited success due to the complexity of etiology involving various inflammation-inducing and -sensitizing molecules acting through redundant mechanisms, necessitating the development of compounds that can effectively modulate immune responses.
Innovation Solution
Administration of immunosuppressive Tat derivative polypeptides, comprising specific domains such as a transcription factor domain, cysteine-rich region, and C-terminal region, which suppress immune responses by enhancing Fas ligand expression on antigen-presenting cell regulatory macrophages, thereby reducing inflammation and autoimmune disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for inflammation and autoimmune disorders, then the complexity of etiology involving various inflammation-inducing and -sensitizing molecules acting through redundant mechanisms remains unaddressed, but treatment effectiveness is limited
Solution Approach 1:
The Tat derivative polypeptide is designed to perform multiple immunomodulatory functions simultaneously: it suppresses antigen-specific immune responses, modulates antigen-presenting cell activity, and regulates inflammatory responses. This multi-functional approach addresses the complex etiology of autoimmune disorders through a single therapeutic agent that can interact with multiple targets in the immune system.
Solution Approach 2:
The patent modifies the amino acid sequence of the Tat protein by substituting specific residues (e.g., substituting lysine at position 10 with arginine, or serine at position 27 with alanine) to optimize its immunosuppressive activity. These parameter changes in the molecular structure enhance the peptide's ability to suppress immune responses while maintaining its ability to address the complex inflammatory pathways involved in autoimmune diseases.
2Object-affected harmful factors
If immunosuppressive therapy is administered to suppress immune responses, then inflammation and autoimmune symptoms are reduced, but patient immunity may be compromised
Solution Approach 1:
The Tat derivative polypeptide is designed to exert partial immunosuppression specifically targeted at pathogenic immune responses rather than complete immunosuppression. It modulates the immune system to reduce harmful inflammatory responses while preserving essential immune functions, achieving a balanced therapeutic effect that addresses autoimmune symptoms without completely compromising patient immunity.
Solution Approach 2:
The patent uses the Tat derivative polypeptide as an intermediary substance that mediates between the overactive immune system and the body's self-tissues. This intermediary agent selectively suppresses pathogenic immune responses against self-antigens while allowing normal immune surveillance and defense functions to continue, thus reducing autoimmune damage without leaving the patient immunocompromised.
Data Source
Figure 1A~1B
Figure 2~3
Figure 4A~4B
AI summary
The present specification provides immunosuppressive Tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodegenerative disease.